Halsey Associates Inc. CT lowered its stake in Allergan plc (NYSE:AGN) by 8.2% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 27,212 shares of the company’s stock after selling 2,431 shares during the period. Halsey Associates Inc. CT’s holdings in Allergan were worth $4,537,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Flagship Harbor Advisors LLC bought a new stake in shares of Allergan in the 2nd quarter worth about $129,000. Kaizen Advisory LLC increased its position in shares of Allergan by 156.2% in the 2nd quarter. Kaizen Advisory LLC now owns 830 shares of the company’s stock worth $138,000 after purchasing an additional 506 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. increased its position in shares of Allergan by 3,193.3% in the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 988 shares of the company’s stock worth $165,000 after purchasing an additional 958 shares during the last quarter. Aries Wealth Management bought a new stake in shares of Allergan in the 2nd quarter worth about $202,000. Finally, Avestar Capital LLC increased its position in shares of Allergan by 46.1% in the 1st quarter. Avestar Capital LLC now owns 1,185 shares of the company’s stock worth $183,000 after purchasing an additional 374 shares during the last quarter. 77.43% of the stock is owned by institutional investors.
Shares of NYSE:AGN opened at $188.22 on Friday. The company has a quick ratio of 0.85, a current ratio of 1.00 and a debt-to-equity ratio of 0.34. Allergan plc has a fifty-two week low of $142.81 and a fifty-two week high of $227.54. The stock has a market cap of $64.61 billion, a P/E ratio of 11.51, a price-to-earnings-growth ratio of 1.46 and a beta of 1.21.
The company also recently announced a quarterly dividend, which will be paid on Monday, September 17th. Shareholders of record on Friday, August 17th will be paid a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a yield of 1.53%. The ex-dividend date is Thursday, August 16th. Allergan’s payout ratio is 17.61%.
Several equities research analysts have recently weighed in on the stock. Mizuho reissued a “hold” rating and issued a $194.00 target price on shares of Allergan in a research report on Monday, July 30th. Credit Suisse Group set a $213.00 target price on shares of Allergan and gave the stock a “buy” rating in a research report on Friday, July 13th. Cantor Fitzgerald set a $180.00 target price on shares of Allergan and gave the stock a “hold” rating in a research report on Monday, August 6th. Wells Fargo & Co reaffirmed a “buy” rating on shares of Allergan in a research report on Monday, June 11th. Finally, Morgan Stanley set a $202.00 price objective on shares of Allergan and gave the company an “overweight” rating in a research report on Thursday, August 23rd. One analyst has rated the stock with a sell rating, six have assigned a hold rating and seventeen have assigned a buy rating to the stock. Allergan has a consensus rating of “Buy” and a consensus target price of $210.10.
In other news, Director Christopher J. Coughlin bought 10,000 shares of Allergan stock in a transaction on Thursday, September 6th. The stock was purchased at an average cost of $190.64 per share, with a total value of $1,906,400.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Joseph H. Boccuzi bought 900 shares of Allergan stock in a transaction on Thursday, August 30th. The shares were purchased at an average cost of $190.59 per share, with a total value of $171,531.00. The disclosure for this purchase can be found here. Insiders own 0.36% of the company’s stock.
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories.
Read More: Google Finance
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.